Brussels, 21/02/2005 (Agence Europe) - Following the meeting on 14-17 February of the Committee for Medicinal Products for Human Use, the European Medicines Agency announced a certain number of provisional measures while awaiting the end of the re-examination of COX-2 inhibitors planned for April 2005. The Committee pointed out that on the basis of the current data, all these kinds of anti-inflammatory products display an increased cardiovascular risk Data also illustrates a link between...